Arkansas Code of 1987 (2023) › Title 23 - PUBLIC UTILITIES AND REGULATED INDUSTRIES (§§ 23-1-101 — 23-119-105) › Subtitle 3 - INSURANCE (§§ 23-60-101 — 23-103-417) › Chapter 63 - INSURANCE COMPANIES GENERALLY (§§ 23-63-101 — 23-63-2010) › Subchapter 17 - PROTECTED CELL COMPANY ACT (§§ 23-63-1701 — 23-63-1709) › Section 23-63-1705 - Use and operation of protected cells

(a)
(1)
The protected cell assets of a protected cell may not be charged with liabilities arising out of any other business the protected cell company may conduct.
(2)
All contracts or other documentation reflecting protected cell liabilities shall clearly indicate that only the protected cell assets are available for the satisfaction of those protected cell liabilities.
(b)
(1)
The income, gains, and losses, realized or unrealized, from protected cell assets and liabilities shall be credited to or charged against the protected cell without regard to other income, gains, or losses of the protected cell company, including income, gains, or losses of other protected cells.
(2)
(A)
Amounts attributed to any protected cell and accumulations on the attributed amounts may be invested and reinvested without regard to any requirements or limitations of §
23-63-801
et seq.
(B)
The investments in a protected cell or protected cells shall not be taken into account in applying the investment limitations applicable to the investments of the protected cell company.
(c)
Assets attributed to a protected cell shall be valued at their fair value on the date of valuation.
(d)
(1)
A protected cell company, in respect to its protected cells, shall engage in fully funded indemnity triggered insurance securitization to support in full the protected cell exposures attributable to that protected cell.
(2)
A protected cell company insurance securitization that is nonindemnity triggered shall qualify as an insurance securitization after the Insurance Commissioner adopts regulations addressing the methods of funding the portion of the risk that is not indemnity based, accounting, disclosure, risk-based capital treatment, and assessing risks associated with such securitizations.
(3)
A protected cell company insurance securitization that is not fully funded, whether indemnity triggered or nonindemnity triggered, is prohibited.
(4)
(A)
Protected cell assets may be used to pay interest or other consideration on any outstanding debt or other obligation attributable to that protected cell.
(B)
Nothing in this subsection shall prevent a protected cell company from entering into a swap agreement or other transaction for the account of the protected cell that has the effect of guaranteeing interest or other consideration.
(e)
(1)
In all protected cell company insurance securitizations, the contracts or other documentation effecting the transaction shall contain provisions identifying the protected cell to which the transaction will be attributed.
(2)
The contracts or other documentation shall clearly disclose that the assets of that protected cell, and only those assets, are available to pay the obligations of that protected cell.
(3)
Failure to include the language required by this subsection in the contracts or other documentation shall not be used as the sole basis by creditors, reinsurers, or other claimants to circumvent the provisions of this subchapter.
(f)
(1)
A protected cell company shall be authorized to attribute to a protected cell account only the insurance obligations relating to the protected cell company's general account.
(2)
A protected cell shall not be authorized to issue insurance or reinsurance contracts directly to policyholders or reinsureds or to have any obligation to the policyholders or reinsureds of the protected cell company's general account.
(g)
At the cessation of business of a protected cell, the protected cell company shall voluntarily close out the protected cell account.
Amended by Act 2021, No. 481,§ 2, eff. 7/28/2021.
Acts 2001, No. 1428, § 5.